{"title": "Cancer Center Highlights Report", "author": null, "url": "https://cancer.montefioreeinstein.org/", "hostname": "montefioreeinstein.org", "description": null, "sitename": "cancer.montefioreeinstein.org", "date": "2023-08-08", "cleaned_text": "We're ranked in the top 1% of all U.S. hospitals for cancer care, according to U.S. News & World Report-and in the top 5% of National Cancer Institute (NCI)-designated cancer centers. Cancer Clinical Trials - [Blood & Bone Marrow Cancers](https://research.montefioreeinstein.org/ct-search?category=Cancer&subCategory=Blood%20%26%20Bone%20Marrow%20Cancers) - [Brain, Spine & Central Nervous System Cancers](https://research.montefioreeinstein.org/ct-search?category=Cancer&subCategory=Brain%2C%20Spine%20%26%20Nerve%20Cancers) [Sarcomas](https://research.montefioreeinstein.org/ct-search?category=Cancer&subCategory=Sarcomas) - [Skin Cancer](https://research.montefioreeinstein.org/ct-search?category=Cancer&subCategory=Skin%20Cancer) Treating More Than 200 Types of Cancer Over 320 Active Clinical Trials Navigating Your Cancer Care At Montefiore Einstein Cancer Center, you receive evidence-based cancer care that addresses the unique needs of each individual patient. Our NCI-designated cancer center brings the worlds of clinical care and academic research together and allows for the translation of novel, cutting-edge scientific discoveries into improved clinical outcomes and new life-saving treatments. Using a multidisciplinary team of disease-focused experts, our full-service cancer center is focused on the prevention, early diagnosis and treatment of cancer while incorporating a comprehensive spectrum of traditional and holistic care. This allows us to deliver highly specialized and coordinated compassionate care for the whole person, address complex medical needs and improve the quality of life for each and every patient. Over 50 Years of Cancer Research and Treatment Breakthroughs Our Latest Research Advancing human health, scientific discovery and innovation through cancer research Leaders in the Science of Cancer Care At Montefiore Einstein Cancer Center, we're committed to finding new and better cancer treatment options. Our research breakthroughs continue to lead to game-changing cancer treatment practices and give patients a chance to join upcoming clinical trials, which may offer potentially successful treatment options. We've received accreditation from the NCI for the past 50 years in a row. Our facility is one of only 71 NCI-designated centers across the United States-and the only one located between Manhattan and New Haven. We made that expansion from Manhattan to Westchester to provide convenient access to cancer patients across the region. State-of-the-Art Technology At Montefiore Einstein Cancer Center, we are proud to provide patients with the newest technology available and offer the latest surgical and therapeutic techniques. Our goal is to utilize the least invasive solutions for your cancer care. That is why we offer the latest in image-guided, immuno-, cellular and targeted therapies, to name just a few. Some of our other molecular imaging technology includes the latest three-dimensional systems for bioluminescence imaging (BLI), fluorescence molecular imaging and single-photon emission computed tomography (SPECT). Committed to Moving Faster Than Cancer Cancer Center Highlights Report Our Highlights Report documents our remarkable innovations in research, treatment and care. - $82M in cancer relevant funding, of which $33 million is dedicated to philanthropy - 1,000+ patients enrolled in clinical research studies - 400 papers published annually in high impact peer-reviewed journals - 200+ types of cancer treated $82M in cancer relevant funding, of which $33 million is dedicated to philanthropy 1,000+ patients enrolled in clinical research studies 400 papers published annually in high impact peer-reviewed journals 200+ types of cancer treated See how the past couple of years have been a remarkable time of vision and growth. Meet Your Cancer Care Team Montefiore Einstein Cancer Center is home to 14 teams of award-winning, multidisciplinary experts who will develop a highly personalized treatment plan specific to your particular type of cancer, including those considered rare. Schedule a Consultation. Consultations are available in person, by phone or by video visit. Contact us today to schedule a consultation. Events at Montefiore Einstein Cancer Center Featured Cancer Clinical Trials [](https://research.montefioreeinstein.org/ct-search/study/NCT03709680) - Childhood Cancers Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors - Start Date May 24, 2019 - Conditions Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Glioma of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer - Start Date August 5, 2022 - Conditions Advanced or Metastatic Non-small Cell Lung Cancer [](https://research.montefioreeinstein.org/ct-search/study/NCT05382286) - Breast Cancer Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer - Start Date July 5, 2022 - Conditions Triple Negative Breast Cancer, PD-L1 Positive [](https://research.montefioreeinstein.org/ct-search/study/NCT05337137) - Liver Cancer A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer - Start Date May 5, 2022 - Conditions Carcinoma, Hepatocellular [](https://research.montefioreeinstein.org/ct-search/study/NCT05360680) - Colorectal Cancer - Gastric Cancer - Pancreatic Cancer - Ovarian Cancer A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers - Start Date June 14, 2022 - Conditions Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer [](https://research.montefioreeinstein.org/ct-search/study/NCT05256290) - Lung Cancer - Brain Cancer A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer - Start Date March 31, 2022 - Conditions Non-Small Cell Lung Cancer, Glioblastoma, EGFR Gene Mutation, Recurrent Glioblastoma, GBM, Advanced Solid Tumor, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC [](https://research.montefioreeinstein.org/ct-search/study/NCT05451849) - Ovarian Cancer - Pancreatic Cancer - Colorectal Cancer A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer - Start Date June 21, 2022 - Conditions Mesothelioma, Mesotheliomas Pleural, Ovarian Serous Adenocarcinoma, Triple Negative Breast Cancer [](https://research.montefioreeinstein.org/ct-search/study/NCT05005728) - Prostate Cancer XmAb\u00ae20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer - Start Date October 22, 2021 - Conditions Metastatic Castration-Resistant Prostate Cancer "}